JNJ logoJNJ
Johnson & Johnson

47,779
Loading...
Loading...
News
all
press releases
BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?
Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?
Black Diamond focuses on silevertinib for NSCLC and GBM, with key trial readouts due in late 2025 and FDA feedback expected in 2026.
Zacks·3d ago
News Placeholder
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.
Zacks·3d ago
News Placeholder
J&J Gears Up for Some Key New Drug Approvals and Launches
JNJ believes 10 of its new products and pipeline candidates can deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta and others.
Zacks·4d ago
News Placeholder
Glaukos Builds Dual Growth Engines Amid Market Headwinds
GKOS raises revenue guidance after record 1H sales, fueled by iDose TR adoption and expanding international glaucoma momentum.
Zacks·5d ago
News Placeholder
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.
Zacks·5d ago
News Placeholder
J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure
JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.
Zacks·9d ago
News Placeholder
ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?
AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.
Zacks·9d ago
News Placeholder
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks·9d ago
News Placeholder
Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue?
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·10d ago

Latest JNJ News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.